# Zero Mention: Alto Didn't Flag Failing Drug in $120M Filing - Date: 2026-04-02 - Category: Biotech & Life Sciences ALTO-101 missed its primary endpoint in schizophrenia patients — but showed a signal in the sickest subgroup with no GI side effects. Alto is now looking for a buyer. ---